2. >>Legal & IP

Teva Settles With San Francisco But New York Could Be Set To Prize Open Old Wounds

Shadow Of The Opioid Crisis Looms Large Over Israeli Generics Firm

 
• By Chloe Kent

Teva has settled the final outstanding advanced US state-level opioid-related case against the firm, but recent allegations from the New York attorney general could see the firm back in court sooner rather than later.

Lady Justice statue
Teva has settled multiple opioid cases raised against the firm • Source: Shutterstock

The final advanced state-level opioid-related claim outstanding against Israeli generics firm Teva has now been settled, with the firm agreeing to pay the county and city of San Francisco $24.8m over the next 13 years to resolve its share of the litigation. It will also supply the state with $20m of its generic version of opioid-overdose nasal spray Narcan (naloxone hydrochloride) over the next decade.

While the firm has expressed that it hopes to make a nationwide settlement by the end of the year, the opioids chapter in Teva’s story still appears far from its conclusion. The New York attorney general Letitia James has now alleged that Teva Pharmaceutical Industries, Ltd. – the Israel-based parent company of Teva Pharmaceuticals USA Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ Claims

 
• By Dean Rudge

Hikma said it would admit no wrongdoing or liability after reaching a preliminary settlement agreement over illicit ‘pay-for-delay’ claims involving its US version of Xyrem “that protects the company’s interests and provides clarity to our stakeholders.”

Viatris Pens Aprepitant Settlement Agreement After Kabi Loses Initial Patent Case

 
• By Dean Rudge

Viatris will look to introduce generic versions of Heron Therapeutics’ aprepitant brands, Cinvanti and Aponvie, around three years before patent expiry after settling litigation with the originator. Other court cases remain ongoing.

J&J Denied Injunction Over Private-Label Ustekinumab In US

 
• By Dave Wallace

Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.

UK Forxiga SPCs Wiped Out As Trio Succeed With Plausibility Attack

 
• By Dean Rudge

Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.

More from Generics Bulletin